Here’s What Hit Baxter (BAX) in Q4

Group 1 - Pzena Focused Value Strategy underperformed the Russell 1000® Value Index in Q4 2025, with a net return of 2.5% compared to the Index's 3.8% [1] - The firm identifies appealing valuation differences in the current market environment, which is seen as favorable for long-term value investors [1] - Baxter International Inc. (NYSE:BAX) was highlighted as a leading performance detractor, with a one-month return of -3.31% and a 52-week loss of 36.76% [2] Group 2 - Baxter's stock closed at $19.87 per share on February 2, 2026, with a market capitalization of $10.214 billion [2] - The healthcare sector, including Baxter, faced challenges due to disappointing third-quarter results and a dividend cut, alongside delayed normalization of IV fluid volumes [2] - The number of hedge funds holding Baxter increased from 31 to 38 in the third quarter, indicating growing interest despite its underperformance [3]